Literature DB >> 11087228

Antiproliferative effect of UTP on human arterial and venous smooth muscle cells.

P J White1, R Kumari, K E Porter, N J London, L L Ng, M R Boarder.   

Abstract

We have investigated the hypothesis that responses associated with proliferation are regulated by extracellular nucleotides such as ATP and UTP in cultured human vascular smooth muscle cells (VSMC) derived from internal mammary artery (IMA) and saphenous vein (SV). Platelet-derived growth factor (PDGF), ATP, and UTP each generated an increase in cytosolic free Ca(2+) concentration ([Ca(2+)](i)) in both IMA- and SV-derived cells in the absence of detectable inositol 1,4,5-trisphosphate production. ATP alone had no effect on [(3)H]thymidine incorporation into DNA, but with a submaximal concentration of PDGF it raised [(3)H]thymidine incorporation in SV- but not IMA-derived cells. UTP alone also was without effect on [(3)H]thymidine incorporation or cell number. However, in both SV- and IMA-derived cells, UTP reduced the PDGF-stimulated [(3)H]thymidine response and PDGF-stimulated cell proliferation. This cannot be explained by an inhibitory effect on the p42/p44 mitogen-activated protein kinase (MAPK) cascade, since this response to PDGF was not attenuated by UTP. We conclude that, in human VSMC of both arterial and venous origin, UTP acts as an anti-proliferative regulator.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11087228     DOI: 10.1152/ajpheart.2000.279.6.H2735

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  8 in total

Review 1.  P2 receptors: intracellular signaling.

Authors:  Laurie Erb; Zhongji Liao; Cheikh I Seye; Gary A Weisman
Journal:  Pflugers Arch       Date:  2006-04-04       Impact factor: 3.657

Review 2.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

3.  Interaction of purinergic receptors with GPCRs, ion channels, tyrosine kinase and steroid hormone receptors orchestrates cell function.

Authors:  Paola Scodelaro Bilbao; Sebastián Katz; Ricardo Boland
Journal:  Purinergic Signal       Date:  2011-09-02       Impact factor: 3.765

Review 4.  P2 receptors: new potential players in atherosclerosis.

Authors:  Francesco Di Virgilio; Anna Solini
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

5.  Functional analysis of a mutant form of the receptor tyrosine kinase Tie2 causing venous malformations.

Authors:  Paul N Morris; Benjamin J Dunmore; Amir Tadros; Douglas A Marchuk; Diane C Darland; Patricia A D'Amore; Nicholas P J Brindle
Journal:  J Mol Med (Berl)       Date:  2004-10-29       Impact factor: 4.599

6.  In-vitro Release of Rapamycin from a Thermosensitive Polymer for the Inhibition of Vascular Smooth Muscle Cell Proliferation.

Authors:  Weiwei Zhu; Takahisa Masaki; Alfred K Cheung; Steven E Kern
Journal:  J Bioequivalence Bioavailab       Date:  2009-05-09

7.  P2 receptors in atherosclerosis and postangioplasty restenosis.

Authors:  Cheikh I Seye; Qiongman Kong; Ningpu Yu; Fernando A Gonzalez; Laurie Erb; Gary A Weisman
Journal:  Purinergic Signal       Date:  2006-06-14       Impact factor: 3.765

8.  P2 receptors in atherosclerosis and postangioplasty restenosis.

Authors:  Cheikh I Seye; Qiongman Kong; Ningpu Yu; Fernando A Gonzalez; Laurie Erb; Gary A Weisman
Journal:  Purinergic Signal       Date:  2007-02-28       Impact factor: 3.765

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.